{"name":"Karyopharm Therapeutics","slug":"karyopharm","ticker":"KPTI","exchange":"NASDAQ","domain":"karyopharm.com","description":"Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and ","hq":"Newton, MA","founded":0,"employees":"228","ceo":"Richard Paulson","sector":"Oncology Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":9.11,"stockChange":0.26,"stockChangePercent":2.94,"marketCap":"$205M","metrics":{"revenue":146067008,"revenueGrowth":11.6,"grossMargin":9.9,"rdSpend":125617000,"netIncome":-196039000,"cash":63744000,"dividendYield":0,"peRatio":-2.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Xpovio patent cliff ($173.4M at risk)","drug":"Xpovio","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"KCP-330","genericName":"KCP-330","slug":"kcp-330","indication":"Other","status":"phase_1"},{"name":"Matching placebo for selinexor","genericName":"Matching placebo for selinexor","slug":"matching-placebo-for-selinexor","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"KCP-330","genericName":"KCP-330","slug":"kcp-330","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Matching placebo for selinexor","genericName":"Matching placebo for selinexor","slug":"matching-placebo-for-selinexor","phase":"phase_3","mechanism":"This is a matching placebo control used in clinical trials for selinexor, not an active drug.","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Karyopharm Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Karyopharm reported fourth quarter and full year 2023 financial results, with net product revenue of $44.4 million for the fourth quarter and $173.4 million for the full year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Karyopharm Therapeutics Announces Collaboration with Incyte Corporation to Develop and Commercialize Selinexor in Combination with Incyte's Luspatercept","summary":"Karyopharm announced a collaboration with Incyte to develop and commercialize selinexor in combination with luspatercept for the treatment of myelodysplastic syndromes and other hematologic malignancies.","drugName":"","sentiment":"positive"},{"date":"2023-09-14","type":"regulatory","headline":"Karyopharm Therapeutics Announces FDA Approval of Xpovio (selinexor) for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","summary":"Karyopharm announced FDA approval of Xpovio for the treatment of relapsed or refractory diffuse large B-cell lymphoma.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPWXltbXltM2tBbm1QLUpWZmpQYXB2LS0wb1RhXzlwRl9YY2ZPTnpidGpOXzI2R2FNRk5MdDE1RWJtTlBhM3dDb3dwdWR5UW5RbERUMjlOTU9oQ0E5eHdmRnRkOEd0Ymx0RTF4R21IWkt2cFd0cmZDVmk4VkNmY0ViT1Uwby1WMzU1SVpyYW5oakFSdTRlLWtJQWMzaUx6UFloNzc5WDdzM25scmlQbVYwZTVPREZnQlBjcFNRekVn?oc=5","date":"2026-03-24","type":"pipeline","source":"PR Newswire","summary":"Karyopharm Announces $30 Million Private Placement with RA Capital - PR Newswire","headline":"Karyopharm Announces $30 Million Private Placement with RA Capital","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQdlVKZzVGZUVsM2Y5LUM2YjZQRkRzOGZGVG1XQzFIV1cyVFVjZXdfeW9WblN3RFBSMEpOUDdXNndaZ3VSYTdxeGM3VHJTTUtvR2w1TG9yck1OSURPV1BMZ3N0eW5BNWg3WTlDMTRSSTdSeXMyYUF5NFVSUktPTVhBN1BudjlhN2tHdm5QS05LWE05R1dTeWViTFNNUVNYbzRjQ0RDcEtBaWJfTmNDRnRnZUhTbUZFWUI0N0RNcTBScXVMeTNSWFlyc1kxS2t6SkFoSnp2Wg?oc=5","date":"2026-03-02","type":"pipeline","source":"PR Newswire","summary":"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire","headline":"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQbFVpaDVZRzFmdm9VamtFdEE5dFpIbkhqMFNvZXZIcVhNb2ZLMUxId1U1ZTVTcjN3RWpwSC1peVhuTExNYkFodnlfVzlMaklRM1FoblY5UVhsR0lRblZVaDFmT00tUDItV0Fwb1VValcxZktrSmhOZ1BsQ1h1SFA1Y0VsaGdBM2ZWN1BMUGNkY1dfZWoxVjl6WkZITXVzbGtMRmQzbVlIN1JXNjl1VkF5eWF4ZjBmZEpWZkJsVFFDa01zV1piQmxjZzdhZURyQkNwZXVmWHNfYU1PY21Pc3k2MlJ0NnVNWHZp?oc=5","date":"2026-02-12","type":"earnings","source":"Karyopharm","summary":"Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - Karyopharm","headline":"Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNZ2lic1pVeGY0U0JSYjU5RE44UmZzemN1UWlFckZQYlpmckU0Zml5NXpDaWJPYVI5S3ZpLVh3UExRcldvaU5GLThqMHZHajlHWVl3TG9sZEVKYS1HNVB3YnBOMzF6amNrbC1YUVpoVlhIVVdZOTlNcWhFTk8tVklFNXhZbU5HSU5pYVI3MlN3Z3ZYeWR1M3RzOTBmMVNzMExMYUxHa3JsOXAzOVZJaUl6LWduTDdzQXVSYkUtelliZFpUODdwMjIwWXhXeU1TM21kMG9r?oc=5","date":"2026-02-05","type":"earnings","source":"Karyopharm","summary":"Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Karyopharm","headline":"Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOMXNtSHAyRUpKS1ZTcHRQWlR5eW5yY1ZsQnVuTUFSY0xlUHZfNUp3eVFOMmphMkNwV3FyT2o4WFUxOGNfV1BSZUdveHdVcWRKZmRvNnJtVmsxMnN5WGNTSEVLODhGeG01aEd0OUxkbzhjaW9yMFhXWEdZZjFtRkk0akRnbEd6TkFzTEhYRl9MaXk1alY2aTJiRjNnRHp3SlpITU5jZ1ZKRQ?oc=5","date":"2025-12-08","type":"pipeline","source":"Karyopharm","summary":"Karyopharm to Participate in Baird's Biotech Discovery Series - Karyopharm","headline":"Karyopharm to Participate in Baird's Biotech Discovery Series","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gJBVV95cUxQelZqMlBKS0FWUzFERjFkdDNBNUx4VUtJZHZUVGxnTVZMTXVod1NfZnM5TVd5UlgtVTZIcG0xdmtpV1JNMUktdmR4MDBMNmdYR0VFeHNSYXdiUkVIUWsxNll4MGpjMVo0X0pFRnZHa0ppUUx3T3ZQMFB2MnNUbXc0QUszNmtTM3RXZ2k5dlhiRlVRbHZXV3FsWVFKdUkzQmJUajhiSU5VdGM4VUpRd21mZDJXQzZFX1J5OTdCZHRZOTVnMzJrNDg1cUFmcW5DWDM4THNPNk03cW1VV3U1QjlLdU40bzFpS05wX05VM2VDZmdxVV8yX3pYRFBuYlkzZXlvNDRlY0YwNlM4d3BqWXZKc2tDLXNpb0IyLUNYY3JSMTFyaFBGa1dVbTBVbDVaTWdhZmkwWi13SEVKTWl0Sm16MXhkZHozY3NxZndLRXJZNUp2cUpnOUZKN0J3?oc=5","date":"2025-10-08","type":"trial","source":"Karyopharm","summary":"Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis - Ka","headline":"Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQbEZxanhLRFpQeEJ1OXFHU1VsZ2lCZXdRQWZNT0xBTzFGRFc2VTN2VWUzMHVudW5kbjNFVkFkNXkzWDdwUENhYTNIazhwVFBwY2JOOU1HWllvQ1dGbkJHTlNnZk1YYVdQZ1Ytd0JnR3RxYU9IWjZhZ3lPMHJabzdLeUlZYTFkUWY2MjhqU3REOEJ0S0Z1a3ZGcHF0emlaXzl6Q3JEWWhaRlNqS2x5TFJoMl9Jc3NTYmVkQ0JQaU5FX2xOeDc1M0VTUk4yZ1hLV2NBVUpTcGlBSXR6WVRndVBxb0NIQWRXUQ?oc=5","date":"2025-08-11","type":"earnings","source":"PR Newswire","summary":"Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress - PR Newswire","headline":"Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMVRhanRzOFdqV1NCRnJfdlRCLV85aWhnOGNPaWxzSVNJT1JfNmp3OW1ObXN3RVVTcWVUcXd6enJwMGlLbDEyRnlnZGpYTmlIblA5em5aajJzYTdBaEhZRHFUaWlFLWJKaVNPUEJBMUVZSnA3RFlWUE4wV291QXdYUnNERkZCRGpiSEJTZzZQMENvWXpmQ3BONldDclAxUGVIYkdfRjc2VXZaWTVkck9laHV5WlphTU1v?oc=5","date":"2025-05-08","type":"earnings","source":"Karyopharm","summary":"Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 - Karyopharm","headline":"Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9ZQjU5LVhFbThYT3BlV000VHpCZkJWYS1xQmxuZVdWQ05wdXBybzZ1U2c2MUZ0b3RJZjlZZmhBdWl2M2ZpNmhwNlZZUFVZOFNxWThJ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"KPTI Stock Price, News & Analysis - Stock Titan","headline":"KPTI Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"Xpovio","drugSlug":"selinexor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":173400000}],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Celgene","Gilead Sciences"],"therapeuticFocus":["Oncology","Hematology"],"financials":{"source":"sec_edgar+yahoo","revenue":146067000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":146067000,"period":"2025-12-31"},{"value":145237000,"period":"2024-12-31"},{"value":145237000,"period":"2024-12-31"},{"value":146033000,"period":"2023-12-31"},{"value":146033000,"period":"2023-12-31"}],"grossProfit":140118000,"grossProfitHistory":[{"period":"2025-12-31","value":140118000},{"period":"2024-12-31","value":139230000},{"period":"2023-12-31","value":141091000},{"period":"2022-12-31","value":151861000}],"rdSpend":125617000,"rdSpendHistory":[{"period":"2025-12-31","value":125617000},{"period":"2024-12-31","value":143232000},{"period":"2023-12-31","value":138750000},{"period":"2022-12-31","value":148662000}],"sgaSpend":105208000,"operatingIncome":-90707000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-90707000},{"period":"2024-12-31","value":-119443000},{"period":"2023-12-31","value":-129540000},{"period":"2022-12-31","value":-142202000}],"netIncome":-196039000,"netIncomeHistory":[{"period":"2025-12-31","value":-196039000},{"period":"2024-12-31","value":-76422000},{"period":"2023-12-31","value":-143099000},{"period":"2022-12-31","value":-165291000}],"eps":-17.93,"epsHistory":[{"period":"2025-12-31","value":-17.93},{"period":"2024-12-31","value":-13.95},{"period":"2023-12-31","value":-18.79},{"period":"2022-12-31","value":-30.3}],"cash":60540000,"cashHistory":[{"period":"2025-12-31","value":60540000},{"period":"2024-12-31","value":62476000},{"period":"2023-12-31","value":52231000},{"period":"2022-12-31","value":135188000}],"totalAssets":108416000,"totalLiabilities":401342000,"totalDebt":233607000,"equity":-292926000,"operatingCashflow":-75369000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-75369000},{"period":"2024-12-31","value":-127486000},{"period":"2023-12-31","value":-92723000},{"period":"2022-12-31","value":-149554000}],"capex":-142000,"capexHistory":[{"period":"2024-12-31","value":-142000},{"period":"2022-12-31","value":-118000},{"period":"2021-12-31","value":-5712000}],"freeCashflow":-75369000,"dividendsPaid":null,"buybacks":null,"employees":228,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":22772000,"ebit":-89646000,"ebitda":-89627000,"period":"2025-12-31","revenue":34079000,"epsBasic":-5.71,"netIncome":-102198000,"rdExpense":27667000,"epsDiluted":-5.71,"grossProfit":32595000,"operatingIncome":-17844000},{"sga":26607000,"ebit":-22085000,"ebitda":-21964000,"period":"2025-09-30","revenue":44044000,"epsBasic":-3.82,"netIncome":-33127000,"rdExpense":30544000,"epsDiluted":-3.82,"grossProfit":41931000,"operatingIncome":-15220000},{"sga":28477000,"ebit":-25984000,"ebitda":-25906000,"period":"2025-06-30","revenue":37929000,"epsBasic":-4.32,"netIncome":-37252000,"rdExpense":32788000,"epsDiluted":-4.32,"grossProfit":36878000,"operatingIncome":-24387000},{"sga":27352000,"ebit":-12432000,"ebitda":-12354000,"period":"2025-03-31","revenue":30015000,"epsBasic":-2.77,"netIncome":-23462000,"rdExpense":34618000,"epsDiluted":-2.77,"grossProfit":28714000,"operatingIncome":-33256000},{"sga":27190000,"ebit":-19685000,"ebitda":-19604000,"period":"2024-12-31","revenue":30542000,"epsBasic":-3.6,"netIncome":-30780000,"rdExpense":33302000,"epsDiluted":-3.6,"grossProfit":29211000,"operatingIncome":-31281000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":9.11,"previousClose":8.85,"fiftyTwoWeekHigh":10.99,"fiftyTwoWeekLow":3.65,"fiftyTwoWeekRange":"3.65 - 10.99","fiftyDayAverage":7.97,"twoHundredDayAverage":6.84,"beta":0.81,"enterpriseValue":404545120,"forwardPE":-2.1,"priceToBook":-0.57,"priceToSales":1.41,"enterpriseToRevenue":2.77,"enterpriseToEbitda":-4.47,"pegRatio":0,"ebitda":-90411000,"ebitdaMargin":-61.9,"freeCashflow":-49426500,"operatingCashflow":-75369000,"totalDebt":305944992,"debtToEquity":0,"currentRatio":1.12,"returnOnAssets":-41.6,"returnOnEquity":0,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":13.17,"targetHighPrice":16,"targetLowPrice":5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.5,"institutionHeldPercent":58.6,"sharesOutstanding":22551250,"floatShares":15083511,"sharesShort":5293720,"shortRatio":10.26,"shortPercentOfFloat":23.5,"epsTrailing":-17.93,"epsForward":-4.37,"revenuePerShare":13.36,"bookValue":-16,"officers":[{"age":58,"name":"Mr. Richard A. Paulson M.B.A.","title":"President, CEO & Director"},{"age":52,"name":"Mr. Stuart  Poulton","title":"Executive VP & Chief Development Officer"},{"age":47,"name":"Dr. Reshma  Rangwala M.D., Ph.D.","title":"Executive VP, Chief Medical Officer & Head of Research"},{"age":55,"name":"Dr. Sharon  Shacham M.B.A., Ph.D.","title":"Co-Founder & Chairman of Scientific Advisory Board"},{"age":54,"name":"Ms. Lori A. Macomber CPA","title":"EVP, CFO & Treasurer"},{"age":null,"name":"Ms. Kristin  Abate","title":"VP, Chief Accounting Officer & Assistant Treasurer"},{"age":null,"name":"Mr. Brendan Twohig Strong","title":"Senior Vice President of Investor Relations"},{"age":48,"name":"Mr. Michael J. Mano J.D.","title":"Executive VP, Chief Legal Officer & Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.karyopharm.com","phone":"617 658 0600"}}